<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00068341</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000321924</org_study_id>
    <secondary_id>P30CA016042</secondary_id>
    <secondary_id>UCLA-9911084</secondary_id>
    <secondary_id>AVENTIS-GIA-11156</secondary_id>
    <secondary_id>GENENTECH-H2269s</secondary_id>
    <nct_id>NCT00068341</nct_id>
  </id_info>
  <brief_title>Docetaxel and Carboplatin With or Without Trastuzumab Before Surgery in Treating Women With Locally Advanced Breast Cancer</brief_title>
  <official_title>Neoadjuvant Treatment and Molecular Characterization of Locally Advanced Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aventis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Jonsson Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as docetaxel and carboplatin, use different ways
      to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies, such as
      trastuzumab, can locate tumor cells and either kill them or deliver tumor-killing substances
      to them without harming normal cells. It is not yet known whether docetaxel and carboplatin
      are more effective with or without trastuzumab in treating breast cancer.

      PURPOSE: This randomized phase II trial is studying how well giving docetaxel together with
      carboplatin and trastuzumab before surgery works compared to docetaxel and carboplatin alone
      before surgery in treating women with locally advanced breast cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2003</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the Objective Response Rate of Patients Treated With Taxotere/Carboplatin With or Without Herceptin Preoperatively.</measure>
    <time_frame>5 years</time_frame>
    <description>Objective response rate of patients treated with Taxotere/carboplatin with or without Herceptin preoperatively. Objective response equals the combination of complete response (CR), partial response (PR) and marginal response (MR).
Tumor size was assessed by (1) physical examination, (2) mammography and (3) MRI. 5 response groups: complete response (CR), partial response (PR), marginal response (MR), stable disease (SD) &amp; disease progression (DP). Pathologic response assigned into 2 groups: pCR and non-pCR. pCR-no evidence of residual invasive disease in specimen.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Tumor Response by Physical Exam and Imaging Studies</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor Response Assessment</measure>
    <time_frame>5 years</time_frame>
    <description>Measured by physical examination compared to breast mammography and MRI assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinico-histologic Predictors of pCR (Pathologic Complete Response)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathologic Nodal Status</measure>
    <time_frame>5 years</time_frame>
    <description>According to Primary Tumor Response Pathologic lymph node status N0 Axillary and other nearby lymph nodes do not have cancer (when looked at under a microscope) N1 Micrometastases (very small clusters of cancer) OR 1-3 axillary lymph nodes have cancer AND/OR Internal mammary nodes have tiny amounts of cancer found on sentinel node biopsy N2 4-9 axillary lymph nodes have cancer OR Internal mammary nodes have cancer, but axillary lymph nodes do not have cancer N3 10 or more axillary lymph nodes have cancer OR Infraclavicular (under the clavicle) nodes have cancer OR Internal mammary nodes have cancer plus 1 or more axillary lymph nodes have cancer OR 4 or more axillary lymph nodes have cancer plus internal mammary nodes have cancer or micrometastases found on sentinel node biopsy OR Supraclavicular (above the clavicle) nodes have cancer</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">74</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I (neoadjuvant therapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>see intervention description</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (neoadjuvant therapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>please see intervention description</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HER2/neu negative patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>please see intervention description</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>trastuzumab</intervention_name>
    <description>Cycle 5-7 post-op only Day 1 4mg/kg IV Day 8, 15 2mg/kg IV Cycle 8 Cycle 8 Day 1, 8, 15 2mg/kg IV Day 22 6mg/kg IV</description>
    <arm_group_label>Arm II (neoadjuvant therapy)</arm_group_label>
    <other_name>Herceptin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
    <description>Cycle 1-8 Day 1 or 2 AUC = 6 IV</description>
    <arm_group_label>Arm I (neoadjuvant therapy)</arm_group_label>
    <arm_group_label>Arm II (neoadjuvant therapy)</arm_group_label>
    <arm_group_label>HER2/neu negative patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
    <description>Cycle 1-8 Day 1 or 2: 75 mg/m2 IV</description>
    <arm_group_label>Arm I (neoadjuvant therapy)</arm_group_label>
    <arm_group_label>Arm II (neoadjuvant therapy)</arm_group_label>
    <arm_group_label>HER2/neu negative patients</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>trastuzumab</intervention_name>
    <description>Cycle 1-4 pre-op Day 1 4mg/kg IV Day 8, 15 2mg/kg IV
Cycle 5-7 post-op Day 1 4mg/kg IV Day 8, 15 2mg/kg IV
Cycle 8 Day 1, 8, 15 2mg/kg IV Day 22 6mg/kg IV</description>
    <arm_group_label>Arm I (neoadjuvant therapy)</arm_group_label>
    <other_name>Herceptin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed infiltrating adenocarcinoma of the breast

          -  Primary breast cancer &gt; 5cm, or skin/chest wall involvement, any N, without evidence
             of metastasis.

          -  No prior radiation to the involved breast

          -  ECOG (Electrocochleography) performance status 0-2

          -  Age 18 years to 80 years

          -  Absolute Neutrophil count &gt; 1500 cell/μl, platelet count &gt; 100000 cells/μl and
             hemoglobin &gt; 9 g/dl

          -  All liver function tests &lt; upper limit of normal

          -  Serum creatinine &lt; 2.0 mg/dl

          -  Normal left ventricular ejection fraction (LVEF) as determined by MUGA (Multiple Gated
             Acquisition) scan or echocardiogram

          -  HER-2/neu status is determined by a FISH (Fluorescence in situ hybridization) test.
             [FISH (+) is HER-2/neu (+)]

          -  If female of childbearing potential, pregnancy test is negative

          -  If premenopausal and not surgically sterilized, the patient agrees to use effective
             birth control method for the duration of the study

          -  Informed consent has been obtained

        Exclusion Criteria:

          -  Non-confirmed infiltrating adenocarcinoma breast cancer

          -  Evidence of metastasis

          -  Previous chemotherapy using the drugs proposed in this study, specifically Herceptin®,
             Taxotere®, and/or Carboplatin

          -  Prior radiation to the involved breast

          -  Recent breast cancer drug therapy within last 5 years of any form

          -  History of allergy to polysorbate or castor oil

          -  Ongoing active infection

          -  Concurrent life-limiting disease with a life expectancy of less than one year

          -  Past or current history of other malignancy within the past 5 years which could affect
             the diagnosis or assessment of breast cancer, except for curatively treated
             non-melanoma skin cancer and/or in situ carcinoma of the cervix

          -  Pregnancy, nursing, fertile women who do not use birth control device

          -  Inability to give informed consent

          -  Patients with pre-existing peripheral neuropathy &gt; grade 2
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Helena R. Chang, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arkansas Cancer Research Center at University of Arkansas for Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USC/Norris Comprehensive Cancer Center and Hospital</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90089-9181</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center at UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wilshire Oncology Medical Group, Incorporated - Pomona</name>
      <address>
        <city>Pomona</city>
        <state>California</state>
        <zip>91767-3021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 10, 2003</study_first_submitted>
  <study_first_submitted_qc>September 10, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2003</study_first_posted>
  <results_first_submitted>February 11, 2016</results_first_submitted>
  <results_first_submitted_qc>February 3, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 27, 2017</results_first_posted>
  <last_update_submitted>February 3, 2017</last_update_submitted>
  <last_update_submitted_qc>February 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>stage IIIC breast cancer</keyword>
  <keyword>stage II breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Dates of recruitment period: 2002-2007 Types of location: oncology outpatient clinics</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm I (Neoadjuvant Therapy)</title>
          <description>see intervention description
carboplatin: Cycle 1-8 Day 1 or 2 AUC = 6 IV (AUC = area under the curve, total drug exposure over time)
docetaxel: Cycle 1-8 Day 1 or 2: 75 mg/m2 IV
trastuzumab: Cycle 1-4 pre-op Day 1 4mg/kg IV Day 8, 15 2mg/kg IV
Cycle 5-7 post-op Day 1 4mg/kg IV Day 8, 15 2mg/kg IV
Cycle 8 Day 1, 8, 15 2mg/kg IV Day 22 6mg/kg IV</description>
        </group>
        <group group_id="P2">
          <title>Arm II (Neoadjuvant Therapy)</title>
          <description>please see intervention description
trastuzumab: Cycle 5-7 post-op only Day 1 4mg/kg IV Day 8, 15 2mg/kg IV Cycle 8 Cycle 8 Day 1, 8, 15 2mg/kg IV Day 22 6mg/kg IV
carboplatin: Cycle 1-8 Day 1 or 2 AUC = 6 IV
docetaxel: Cycle 1-8 Day 1 or 2: 75 mg/m2 IV</description>
        </group>
        <group group_id="P3">
          <title>HER2/Neu Negative Patients</title>
          <description>please see intervention description
carboplatin: Cycle 1-8 Day 1 or 2 AUC = 6 IV
docetaxel: Cycle 1-8 Day 1 or 2: 75 mg/m2 IV</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm I (Neoadjuvant Therapy)</title>
          <description>see intervention description
carboplatin: Cycle 1-8 Day 1 or 2 AUC = 6 IV
docetaxel: Cycle 1-8 Day 1 or 2: 75 mg/m2 IV
trastuzumab: Cycle 1-4 pre-op Day 1 4mg/kg IV Day 8, 15 2mg/kg IV
Cycle 5-7 post-op Day 1 4mg/kg IV Day 8, 15 2mg/kg IV
Cycle 8 Day 1, 8, 15 2mg/kg IV Day 22 6mg/kg IV</description>
        </group>
        <group group_id="B2">
          <title>Arm II (Neoadjuvant Therapy)</title>
          <description>please see intervention description
trastuzumab: Cycle 5-7 post-op only Day 1 4mg/kg IV Day 8, 15 2mg/kg IV Cycle 8 Cycle 8 Day 1, 8, 15 2mg/kg IV Day 22 6mg/kg IV
carboplatin: Cycle 1-8 Day 1 or 2 AUC = 6 IV
docetaxel: Cycle 1-8 Day 1 or 2: 75 mg/m2 IV</description>
        </group>
        <group group_id="B3">
          <title>HER2/Neu Negative Patients</title>
          <description>please see intervention description
carboplatin: Cycle 1-8 Day 1 or 2 AUC = 6 IV
docetaxel: Cycle 1-8 Day 1 or 2: 75 mg/m2 IV</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="44"/>
            <count group_id="B4" value="74"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="44"/>
                    <measurement group_id="B4" value="74"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="44"/>
                    <measurement group_id="B4" value="74"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="44"/>
                    <measurement group_id="B4" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Evaluate the Objective Response Rate of Patients Treated With Taxotere/Carboplatin With or Without Herceptin Preoperatively.</title>
        <description>Objective response rate of patients treated with Taxotere/carboplatin with or without Herceptin preoperatively. Objective response equals the combination of complete response (CR), partial response (PR) and marginal response (MR).
Tumor size was assessed by (1) physical examination, (2) mammography and (3) MRI. 5 response groups: complete response (CR), partial response (PR), marginal response (MR), stable disease (SD) &amp; disease progression (DP). Pathologic response assigned into 2 groups: pCR and non-pCR. pCR-no evidence of residual invasive disease in specimen.</description>
        <time_frame>5 years</time_frame>
        <population>pCR was not assessed for 2 patients in the HER2 - (Pre-Op TC) group [1 protocol violation, 1 bilateral disease] and for 1 patient in the HER2+ (Pre-Op TC, Post-Op Herceptin) group [protocol violation]</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I: HER2+</title>
            <description>(Pre-Op TCH)</description>
          </group>
          <group group_id="O2">
            <title>Arm II: HER2+</title>
            <description>(Pre-Op TC, Post-Op Herceptin)</description>
          </group>
          <group group_id="O3">
            <title>HER2-</title>
            <description>(Pre-Op TC)</description>
          </group>
          <group group_id="O4">
            <title>Total</title>
          </group>
        </group_list>
        <measure>
          <title>Evaluate the Objective Response Rate of Patients Treated With Taxotere/Carboplatin With or Without Herceptin Preoperatively.</title>
          <description>Objective response rate of patients treated with Taxotere/carboplatin with or without Herceptin preoperatively. Objective response equals the combination of complete response (CR), partial response (PR) and marginal response (MR).
Tumor size was assessed by (1) physical examination, (2) mammography and (3) MRI. 5 response groups: complete response (CR), partial response (PR), marginal response (MR), stable disease (SD) &amp; disease progression (DP). Pathologic response assigned into 2 groups: pCR and non-pCR. pCR-no evidence of residual invasive disease in specimen.</description>
          <population>pCR was not assessed for 2 patients in the HER2 - (Pre-Op TC) group [1 protocol violation, 1 bilateral disease] and for 1 patient in the HER2+ (Pre-Op TC, Post-Op Herceptin) group [protocol violation]</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="42"/>
                <count group_id="O4" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DFS (Disease Free Survival)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="33"/>
                    <measurement group_id="O4" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OS (overall survival)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="39"/>
                    <measurement group_id="O4" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Tumor Response by Physical Exam and Imaging Studies</title>
        <time_frame>5 years</time_frame>
        <population>Clinical response was not assessed for 2 patients in the HER2 - (Pre-Op TC) group [1 protocol violation, 1 bilateral disease] and for 1 patient in the HER2+ (Pre-Op TC, Post-Op Herceptin) group [protocol violation]</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I: Her2+</title>
            <description>all evaluated subjects.</description>
          </group>
          <group group_id="O2">
            <title>Arm II:Her2+</title>
            <description>all evaluated subjects.</description>
          </group>
          <group group_id="O3">
            <title>Arm III: Her2-</title>
            <description>all evaluated subjects.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Tumor Response by Physical Exam and Imaging Studies</title>
          <population>Clinical response was not assessed for 2 patients in the HER2 - (Pre-Op TC) group [1 protocol violation, 1 bilateral disease] and for 1 patient in the HER2+ (Pre-Op TC, Post-Op Herceptin) group [protocol violation]</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Marginal Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tumor Response Assessment</title>
        <description>Measured by physical examination compared to breast mammography and MRI assessment</description>
        <time_frame>5 years</time_frame>
        <population>pCR was not assessed for 2 patients in the HER2 - (Pre-Op TC) group [1 protocol violation, 1 bilateral disease] and for
1 patient in the HER2+ (Pre-Op TC, Post-Op Herceptin) group [protocol violation]&quot;</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I: Her2 +</title>
            <description>all enrolled subjects</description>
          </group>
          <group group_id="O2">
            <title>Arm II: Her2 +</title>
            <description>all enrolled subjects</description>
          </group>
          <group group_id="O3">
            <title>Arm III: Her -</title>
            <description>all enrolled subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Tumor Response Assessment</title>
          <description>Measured by physical examination compared to breast mammography and MRI assessment</description>
          <population>pCR was not assessed for 2 patients in the HER2 - (Pre-Op TC) group [1 protocol violation, 1 bilateral disease] and for
1 patient in the HER2+ (Pre-Op TC, Post-Op Herceptin) group [protocol violation]&quot;</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinico-histologic Predictors of pCR (Pathologic Complete Response)</title>
        <time_frame>5 years</time_frame>
        <population>ER (estrogen-receptor), PR (progesterone-receptor), HER2 (human epidermal growth factor receptor 2), FISH (Fluorescence in situ hybridization), IDC (invasive ductal carcinoma), ILC (invasive lobular carcinoma),</population>
        <group_list>
          <group group_id="O1">
            <title>Pathologic CR - Yes</title>
            <description>All enrolled subjects</description>
          </group>
          <group group_id="O2">
            <title>Pathologic CR - No</title>
            <description>All enrolled subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Clinico-histologic Predictors of pCR (Pathologic Complete Response)</title>
          <population>ER (estrogen-receptor), PR (progesterone-receptor), HER2 (human epidermal growth factor receptor 2), FISH (Fluorescence in situ hybridization), IDC (invasive ductal carcinoma), ILC (invasive lobular carcinoma),</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ER-negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ER-positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR-negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR-positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ER and PR both negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ER and PR one negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ER and PR both positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HER2 negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HER2 positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T-Stage T2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T-Stage T3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T-Stage T4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tumor Type - IDC only</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tumor Type - all others (compared to IDC only)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tumor Type - ILC only</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tumor Type - all other comparted to (ICL only)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triple Negative-yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triple Negative-no</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FISH positive Herceptin No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FISH positive Herceptin Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pathologic Nodal Status</title>
        <description>According to Primary Tumor Response Pathologic lymph node status N0 Axillary and other nearby lymph nodes do not have cancer (when looked at under a microscope) N1 Micrometastases (very small clusters of cancer) OR 1–3 axillary lymph nodes have cancer AND/OR Internal mammary nodes have tiny amounts of cancer found on sentinel node biopsy N2 4–9 axillary lymph nodes have cancer OR Internal mammary nodes have cancer, but axillary lymph nodes do not have cancer N3 10 or more axillary lymph nodes have cancer OR Infraclavicular (under the clavicle) nodes have cancer OR Internal mammary nodes have cancer plus 1 or more axillary lymph nodes have cancer OR 4 or more axillary lymph nodes have cancer plus internal mammary nodes have cancer or micrometastases found on sentinel node biopsy OR Supraclavicular (above the clavicle) nodes have cancer</description>
        <time_frame>5 years</time_frame>
        <population>only 71 subjects of the 74 subjects could be analyzed for this outcome measure due to data collection error.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Pre-op TCH)</title>
            <description>enrolled subjects</description>
          </group>
          <group group_id="O2">
            <title>Her2+ (Pre-op TC, Post-op Herceptin)</title>
            <description>enrolled subjects</description>
          </group>
          <group group_id="O3">
            <title>Her2- (Pre-op TC)</title>
            <description>enrolled subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Pathologic Nodal Status</title>
          <description>According to Primary Tumor Response Pathologic lymph node status N0 Axillary and other nearby lymph nodes do not have cancer (when looked at under a microscope) N1 Micrometastases (very small clusters of cancer) OR 1–3 axillary lymph nodes have cancer AND/OR Internal mammary nodes have tiny amounts of cancer found on sentinel node biopsy N2 4–9 axillary lymph nodes have cancer OR Internal mammary nodes have cancer, but axillary lymph nodes do not have cancer N3 10 or more axillary lymph nodes have cancer OR Infraclavicular (under the clavicle) nodes have cancer OR Internal mammary nodes have cancer plus 1 or more axillary lymph nodes have cancer OR 4 or more axillary lymph nodes have cancer plus internal mammary nodes have cancer or micrometastases found on sentinel node biopsy OR Supraclavicular (above the clavicle) nodes have cancer</description>
          <population>only 71 subjects of the 74 subjects could be analyzed for this outcome measure due to data collection error.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>N(0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 years from 1st study drug administration</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Arm I: HER+ (Pre-Op TCH)</title>
          <description>Arm I carboplatin: Cycle 1-8 Day 1 or 2 AUC = 6 IV docetaxel: Cycle 1-8 Day 1 or 2: 75 mg/m2 IV trastuzumab: Cycle 1-4 pre-op Day 1 4mg/kg IV Day 8, 15 2mg/kg IV</description>
        </group>
        <group group_id="E2">
          <title>Arm II: HER2+ (Pre-Op TC, Post-Op Herceptin)</title>
          <description>Arm II trastuzumab: Cycle 5-7 post-op only Day 1 4mg/kg IV Day 8, 15 2mg/kg IV Cycle 8 Cycle 8 Day 1, 8, 15 2mg/kg IV Day 22 6mg/kg IV carboplatin: Cycle 1-8 Day 1 or 2 AUC = 6 IV docetaxel: Cycle 1-8 Day 1 or 2: 75 mg/m2 IV Cycle 5-7 post-op Day 1 4mg/kg IV Day 8, 15 2mg/kg IV Cycle 8 Day 1, 8, 15 2mg/kg IV Day 22 6mg/kg IV</description>
        </group>
        <group group_id="E3">
          <title>Arm III: HER2- (Pre-Op TC)</title>
          <description>HER2/neu negative patients carboplatin: Cycle 1-8 Day 1 or 2 AUC = 6 IV docetaxel: Cycle 1-8 Day 1 or 2: 75 mg/m2 IV</description>
        </group>
        <group group_id="E4">
          <title>Total</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (Unspecified)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhea and dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Severe Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>hypokalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>pain, swelling, mastectomy site cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>death progressive disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>divetricular abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>febrile neutropenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E4" events="9" subjects_affected="9" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Upper Extremity Cellulites</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4</frequency_threshold>
        <default_vocab>CTCAE (Unspecified)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="45" subjects_at_risk="45"/>
                <counts group_id="E4" subjects_affected="72" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="42" subjects_affected="13" subjects_at_risk="15"/>
                <counts group_id="E2" events="50" subjects_affected="11" subjects_at_risk="14"/>
                <counts group_id="E3" events="83" subjects_affected="32" subjects_at_risk="45"/>
                <counts group_id="E4" events="175" subjects_affected="56" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="29" subjects_affected="7" subjects_at_risk="15"/>
                <counts group_id="E2" events="50" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E3" events="116" subjects_affected="17" subjects_at_risk="45"/>
                <counts group_id="E4" events="195" subjects_affected="28" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="29" subjects_affected="13" subjects_at_risk="15"/>
                <counts group_id="E2" events="50" subjects_affected="7" subjects_at_risk="14"/>
                <counts group_id="E3" events="116" subjects_affected="31" subjects_at_risk="45"/>
                <counts group_id="E4" events="195" subjects_affected="51" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="15"/>
                <counts group_id="E2" events="30" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E3" events="38" subjects_affected="17" subjects_at_risk="45"/>
                <counts group_id="E4" events="75" subjects_affected="28" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="25" subjects_affected="10" subjects_at_risk="15"/>
                <counts group_id="E2" events="35" subjects_affected="8" subjects_at_risk="14"/>
                <counts group_id="E3" events="116" subjects_affected="34" subjects_at_risk="45"/>
                <counts group_id="E4" events="176" subjects_affected="52" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="19" subjects_affected="9" subjects_at_risk="15"/>
                <counts group_id="E2" events="24" subjects_affected="8" subjects_at_risk="14"/>
                <counts group_id="E3" events="52" subjects_affected="22" subjects_at_risk="45"/>
                <counts group_id="E4" events="95" subjects_affected="39" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypergylcemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="12" subjects_affected="6" subjects_at_risk="45"/>
                <counts group_id="E4" events="14" subjects_affected="8" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurry Vision</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Eye Tearing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Vision Change</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E4" events="7" subjects_affected="6" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="10" subjects_affected="6" subjects_at_risk="15"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="14"/>
                <counts group_id="E3" events="52" subjects_affected="24" subjects_at_risk="45"/>
                <counts group_id="E4" events="69" subjects_affected="35" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Indigestion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" events="11" subjects_affected="6" subjects_at_risk="14"/>
                <counts group_id="E3" events="17" subjects_affected="12" subjects_at_risk="45"/>
                <counts group_id="E4" events="31" subjects_affected="20" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Mouth Sore</sub_title>
                <counts group_id="E1" events="18" subjects_affected="10" subjects_at_risk="15"/>
                <counts group_id="E2" events="12" subjects_affected="8" subjects_at_risk="14"/>
                <counts group_id="E3" events="21" subjects_affected="11" subjects_at_risk="45"/>
                <counts group_id="E4" events="51" subjects_affected="29" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="34" subjects_affected="13" subjects_at_risk="15"/>
                <counts group_id="E2" events="45" subjects_affected="12" subjects_at_risk="14"/>
                <counts group_id="E3" events="106" subjects_affected="32" subjects_at_risk="45"/>
                <counts group_id="E4" events="185" subjects_affected="57" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Throat Complaint</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="25" subjects_affected="8" subjects_at_risk="15"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E3" events="30" subjects_affected="16" subjects_at_risk="45"/>
                <counts group_id="E4" events="60" subjects_affected="28" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E4" events="12" subjects_affected="9" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Cold Symptons</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" events="6" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E3" events="13" subjects_affected="7" subjects_at_risk="45"/>
                <counts group_id="E4" events="21" subjects_affected="12" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="15"/>
                <counts group_id="E2" events="15" subjects_affected="5" subjects_at_risk="14"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E4" events="25" subjects_affected="15" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E4" events="11" subjects_affected="7" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="8" subjects_affected="6" subjects_at_risk="45"/>
                <counts group_id="E4" events="9" subjects_affected="7" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Sweats</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E3" events="9" subjects_affected="7" subjects_at_risk="45"/>
                <counts group_id="E4" events="16" subjects_affected="11" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Taste Change</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="15"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="14"/>
                <counts group_id="E3" events="20" subjects_affected="15" subjects_at_risk="45"/>
                <counts group_id="E4" events="35" subjects_affected="26" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Weakness/Fatigue</sub_title>
                <counts group_id="E1" events="34" subjects_affected="13" subjects_at_risk="15"/>
                <counts group_id="E2" events="37" subjects_affected="12" subjects_at_risk="14"/>
                <counts group_id="E3" events="155" subjects_affected="41" subjects_at_risk="45"/>
                <counts group_id="E4" events="226" subjects_affected="66" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Weight Change</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E4" events="7" subjects_affected="6" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALT Elevated</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E2" events="7" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E3" events="13" subjects_affected="8" subjects_at_risk="45"/>
                <counts group_id="E4" events="23" subjects_affected="13" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>APT Elevated</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E3" events="11" subjects_affected="8" subjects_at_risk="45"/>
                <counts group_id="E4" events="15" subjects_affected="12" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>AST Elevated</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E3" events="10" subjects_affected="7" subjects_at_risk="45"/>
                <counts group_id="E4" events="16" subjects_affected="12" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Albumin Decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" events="5" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E3" events="47" subjects_affected="13" subjects_at_risk="45"/>
                <counts group_id="E4" events="56" subjects_affected="17" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Appetite Change</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E3" events="12" subjects_affected="10" subjects_at_risk="45"/>
                <counts group_id="E4" events="20" subjects_affected="16" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E4" events="7" subjects_affected="6" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="19" subjects_affected="5" subjects_at_risk="15"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="14"/>
                <counts group_id="E3" events="26" subjects_affected="19" subjects_at_risk="45"/>
                <counts group_id="E4" events="53" subjects_affected="32" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="12" subjects_affected="6" subjects_at_risk="45"/>
                <counts group_id="E4" events="14" subjects_affected="8" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E4" events="7" subjects_affected="5" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E2" events="7" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E3" events="9" subjects_affected="6" subjects_at_risk="45"/>
                <counts group_id="E4" events="20" subjects_affected="13" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E4" events="7" subjects_affected="5" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E3" events="17" subjects_affected="10" subjects_at_risk="45"/>
                <counts group_id="E4" events="24" subjects_affected="16" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Body Ache</sub_title>
                <counts group_id="E1" events="19" subjects_affected="7" subjects_at_risk="15"/>
                <counts group_id="E2" events="23" subjects_affected="11" subjects_at_risk="14"/>
                <counts group_id="E3" events="35" subjects_affected="19" subjects_at_risk="45"/>
                <counts group_id="E4" events="77" subjects_affected="37" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Chest Complain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="45"/>
                <counts group_id="E4" events="10" subjects_affected="8" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Dry Mucosa</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E3" events="5" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E4" events="8" subjects_affected="6" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E4" events="10" subjects_affected="9" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="15"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E3" events="16" subjects_affected="13" subjects_at_risk="45"/>
                <counts group_id="E4" events="27" subjects_affected="20" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Neuropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Numbness/Tingling</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="15"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="14"/>
                <counts group_id="E3" events="17" subjects_affected="10" subjects_at_risk="45"/>
                <counts group_id="E4" events="32" subjects_affected="22" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E4" events="5" subjects_affected="3" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E3" events="7" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E4" events="14" subjects_affected="10" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Irregular Menstruation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E4" events="7" subjects_affected="6" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Hot Flashes</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="45"/>
                <counts group_id="E4" events="11" subjects_affected="11" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nose Bleed</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E4" events="8" subjects_affected="6" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Shortness of Breath</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="14"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="45"/>
                <counts group_id="E4" events="15" subjects_affected="12" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="15"/>
                <counts group_id="E2" events="21" subjects_affected="11" subjects_at_risk="14"/>
                <counts group_id="E3" events="50" subjects_affected="36" subjects_at_risk="45"/>
                <counts group_id="E4" events="85" subjects_affected="59" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Nail Change</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="14"/>
                <counts group_id="E3" events="12" subjects_affected="11" subjects_at_risk="45"/>
                <counts group_id="E4" events="20" subjects_affected="19" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="14"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E4" events="11" subjects_affected="9" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Skin Changes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot Flashes</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="45"/>
                <counts group_id="E4" events="11" subjects_affected="11" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Helena Chang, M.D., Ph.D., Revlon/UCLA Breast Center</name_or_title>
      <organization>Jonsson Comprehensive Cancer Center</organization>
      <phone>310-794-5640</phone>
      <email>hchang@mednet.ucla.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

